505 related articles for article (PubMed ID: 32009100)
1. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
3. Genetics of MDS.
Ogawa S
Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
[TBL] [Abstract][Full Text] [Related]
4. Genetic basis of myelodysplastic syndromes.
Ogawa S
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(3):107-121. PubMed ID: 32161209
[TBL] [Abstract][Full Text] [Related]
5. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
6. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
7. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
Stosch JM; Heumüller A; Niemöller C; Bleul S; Rothenberg-Thurley M; Riba J; Renz N; Szarc Vel Szic K; Pfeifer D; Follo M; Pahl HL; Zimmermann S; Duyster J; Wehrle J; Lübbert M; Metzeler KH; Claus R; Becker H
Br J Haematol; 2018 Sep; 182(6):830-842. PubMed ID: 29974943
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
Zhang L; Padron E; Lancet J
Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
[TBL] [Abstract][Full Text] [Related]
9. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H; Leung AY; Kwong YL
Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Papaemmanuil E; Gerstung M; Malcovati L; Tauro S; Gundem G; Van Loo P; Yoon CJ; Ellis P; Wedge DC; Pellagatti A; Shlien A; Groves MJ; Forbes SA; Raine K; Hinton J; Mudie LJ; McLaren S; Hardy C; Latimer C; Della Porta MG; O'Meara S; Ambaglio I; Galli A; Butler AP; Walldin G; Teague JW; Quek L; Sternberg A; Gambacorti-Passerini C; Cross NC; Green AR; Boultwood J; Vyas P; Hellstrom-Lindberg E; Bowen D; Cazzola M; Stratton MR; Campbell PJ;
Blood; 2013 Nov; 122(22):3616-27; quiz 3699. PubMed ID: 24030381
[TBL] [Abstract][Full Text] [Related]
12. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
13. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.
Bănescu C; Tripon F; Muntean C
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982819
[TBL] [Abstract][Full Text] [Related]
14. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
15. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
Harada H
Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
[TBL] [Abstract][Full Text] [Related]
16. Genetics of progression from MDS to secondary leukemia.
Menssen AJ; Walter MJ
Blood; 2020 Jul; 136(1):50-60. PubMed ID: 32430504
[TBL] [Abstract][Full Text] [Related]
17. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
Kennedy JA; Ebert BL
J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
[TBL] [Abstract][Full Text] [Related]
19. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
Martín-Izquierdo M; Abáigar M; Hernández-Sánchez JM; Tamborero D; López-Cadenas F; Ramos F; Lumbreras E; Madinaveitia-Ochoa A; Megido M; Labrador J; Sánchez-Real J; Olivier C; Dávila J; Aguilar C; Rodríguez JN; Martín-Nuñez G; Santos-Mínguez S; Miguel-García C; Benito R; Díez-Campelo M; Hernández-Rivas JM
Haematologica; 2021 Aug; 106(8):2215-2223. PubMed ID: 32675227
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
Harada H; Harada Y
Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]